ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zentalis Pharmaceuticals Inc (ZNTL) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no clear technical or proprietary trading signals indicating a strong entry point. Holding off on investment until better signals or financial improvements emerge is recommended.
The MACD histogram is negative (-0.074) and contracting, indicating weak momentum. RSI is neutral at 45.193, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (2.489), with resistance at 2.748 and support at 2.229. Overall, the technical indicators suggest a lack of strong directional movement.
NULL identified. No recent news, insider trading, or significant hedge fund activity. The stock has a moderate chance of gaining 4.76% in the next week based on historical patterns.
Weak financial performance in Q3 2025 with a significant YoY drop in net income (-33.54%) and EPS (-33.93%). Gross margin is 0, indicating no profitability. No recent congress trading data or influential figure activity. Technical indicators and options data do not show strong bullish sentiment.
In Q3 2025, revenue remained at 0 with no YoY growth. Net income dropped to -$26.69M (-33.54% YoY), EPS fell to -0.37 (-33.93% YoY), and gross margin dropped to 0 (-100% YoY). Overall, the financials are weak with no signs of improvement.
No recent analyst rating or price target changes available for ZNTL.
